Menu

Markets

Research

News

Learn
Paper trading
AI Chat
WatchlistsPortfoliosAlerts
Sign in
Advertisement

Market-Moving News for December 15th

Benzinga Newsdesk 10 months ago

MoversTrading Ideas

RADX: 471% | Radiopharm Theranostics' Interim Data From The First Twelve Patients In Its U.S. Phase 2b Imaging Trial Of RAD 101 In Brain Metastases Showed That 92% Of The Patients Achieved Concordance With

RADX: 471% | Radiopharm Theranostics' Interim Data From The First Twelve Patients In Its U.S. Phase 2b Imaging Trial Of RAD 101 In Brain Metastases Showed That 92% Of The Patients Achieved Concordance With MRI

 

MIST: 49% | Reported Friday, Milestone Wins FDA Approval For CARDAMYST, First Self-Administered Nasal Spray For Paroxysmal Supraventricular Tachycardia

 

KYTX: 47% | Kyverna Therapeutics Released Topline Data From KYSA-8 Phase 2 Trial Of Mivocabtagene Autoleucel For Stiff Person Syndrome, Miv-Cel Achieved Statistically Significant Clinical Benefit Across All Primary And Secondary Endpoints

Read the original

Advertisement